Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Mark Ragosa Sells 36,783 Shares of Company Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 36,783 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $92.16, for a total transaction of $3,389,921.28. Following the completion of the transaction, the chief financial officer owned 20,854 shares of the company’s stock, valued at approximately $1,921,904.64. This represents a 63.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded up $2.49 during mid-day trading on Tuesday, reaching $93.29. 1,021,631 shares of the stock were exchanged, compared to its average volume of 705,858. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The company has a market capitalization of $7.28 billion, a P/E ratio of 71.76 and a beta of 0.04. The business’s 50 day moving average is $79.39 and its 200-day moving average is $60.29.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The company had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Canaccord Genuity Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $100.57.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors have recently bought and sold shares of KNSA. Bank of America Corp DE increased its stake in Kiniksa Pharmaceuticals International by 220.9% during the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after buying an additional 506,576 shares in the last quarter. Rubric Capital Management LP raised its holdings in shares of Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after acquiring an additional 421,347 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 213.5% during the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock valued at $23,197,000 after acquiring an additional 327,595 shares during the last quarter. Spruce Street Capital LP lifted its position in shares of Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its position in shares of Kiniksa Pharmaceuticals International by 41.3% in the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after acquiring an additional 251,578 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.